B of A Securities Maintains Neutral on Rhythm Pharmaceuticals, Raises Price Target to $52

Benzinga · 10/14 17:45
B of A Securities analyst Tazeen Ahmad maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Neutral and raises the price target from $48 to $52.